2015至2019年接受治疗的系统性风湿病全因死亡率与一般人群比较
基于希腊近99%人口电子数据库的回顾性队列研究,纳入2015至2019年接受治疗的类风湿关节炎、强直性脊柱炎、银屑病关节炎、系统性红斑狼疮和系统性硬化症患者,按性别年龄1:5匹配一般人群。5年观察期内,炎症性关节炎死亡率与一般人群相当或略高,而系统性红斑狼疮和系统性硬化症全因死亡率分别约为一般人群的2倍和4倍,男性和年轻患者更高。
要点
- 炎症性关节炎(强直性脊柱炎/银屑病关节炎)5年生存率与一般人群相当,类风湿关节炎略高。
- 系统性红斑狼疮和系统性硬化症全因死亡率分别约为一般人群的2倍和4倍。
- 系统性红斑狼疮和系统性硬化症中男性和50岁以下患者死亡率更高。
核心结论
- 接受治疗的炎症性关节炎5年生存率目前与一般人群相当(强直性脊柱炎/银屑病关节炎)或略高(类风湿关节炎)。
- 系统性红斑狼疮和系统性硬化症全因死亡率分别约为一般人群的2倍和4倍,男性和年轻患者更高。
研究设计与样本
- 基于希腊覆盖近99%人口的电子数据库的回顾性队列研究,纳入2015至2019年接受治疗的患者:类风湿关节炎42735例(女性79%)、强直性脊柱炎9707例(女性43%)、银屑病关节炎13779例(女性55%)、系统性红斑狼疮10440例(女性89%)、系统性硬化症2277例(女性88%),研究入组中位年龄分别为64/47/54/53/59岁。
- 按性别和年龄1:5(患者:一般人群)匹配后进行比较。
主要发现
- 生存率从差到好依次为系统性硬化症、系统性红斑狼疮、炎症性关节炎。
- 观察期从最初3年至5年,死亡HR升高:类风湿关节炎从0.63升至1.13(95% CI: 1.05至1.22),强直性脊柱炎从0.62升至1.01(95% CI: 0.76至1.33),银屑病关节炎从0.68升至1.06(95% CI: 0.88至1.28),系统性红斑狼疮从1.52升至1.98(95% CI: 1.67至2.33),系统性硬化症从2.27升至4.24(95% CI: 3.19至5.63)。
- 系统性红斑狼疮和系统性硬化症中男性和50岁以下患者死亡率高于女性和年长患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare current all-cause mortality rates in rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) versus general population. METHODS: In this population-based, retrospective cohort study, anonymised data on 11 186 586 citizens, including all patients with RA (42 735, 79% female), AS (9707, 43% female), PsA (13 779, 55% female), SLE (10 440, 89% female) and SSc (2277, 88% female), (median age of 64/47/54/53/59 years at study entry, respectively), under prescribed treatment between 2015 and 2019, were extracted from the electronic database covering nearly 99% of the Greek population. RESULTS: After 1:5 (patients:general population) matching for gender/age, we found that survival was worse in SSc, followed by SLE and inflammatory arthritis. Compared with the general population HRs for death increased from the first 3 years to 5 years of observation possibly due to increases in disease duration: RA (from 0.63 to 1.13 (95% CI: 1.05 to 1.22), AS (from 0.62 to 1.01, (95% CI: 0.76 to 1.33)), PsA (from 0.68 to 1.06, (95% CI: 0.88 to 1.28)), SLE (from 1.52 to 1.98, (95% CI: 1.67 to 2.33)) and SSc (from 2.27 to 4.24, (95% CI: 3.19 to 5.63)). In both SLE and SSc mortality was increased in men than women and in patients younger than 50 years. CONCLUSIONS: Survival rates over 5 years in inflammatory arthritis under treatment are currently becoming comparable (AS/PsA) or slightly higher (RA) than those of the general population. However, all-cause mortality is almost twofold and fourfold higher in SLE and SSc, respectively, being even higher for male and younger patients.
引用
- Bournia VK, Fragoulis GE, Mitrou P, et al. All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015-2019. RMD Open. 2021. PMID: 34728554. doi:10.1136/rmdopen-2021-001694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。